American Association of Cancer Research highlights article published by Phase Holographic Imaging collaborators
In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nanomedicine against ovarian cancer developed by scientists from the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University. Phase Holographic Imaging maintains the Holographic Imaging Cytometry Program of Excellence at the University since 2014. For more information about the article see dx.doi.org/10.1158/1535-7163.MCT-15-0986.
Ovarian cancer is the deadliest gynecologic malignancy in developed countries. It has a 5-year survival rate of approximately 40% and accounts for 6% of all cancer-related deaths in women in the United States. A combination chemotherapy prolongs the lives of patients. However, the disease recurs in 80% of cases because the tumor cells develop drug resistance.
Using HoloMonitor® M4 the researchers at the University of Chicago and Northeastern University have shown that the new treatment prevents recurring tumor growth by stopping drug resistant cells from dividing.
“In total, customers and partners have published over 60 scientific publications were the company’s technology is used. The publications, which are reviewed by independent scientists, show the scientific value of our HoloMonitor technology and thereby its market potential within cancer research and other research fields”, said CEO Peter Egelberg.
A list of the scientific publications can be found at www.phiab.se/publications/articles.
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: peter.egelberg@phiab.se
Web: www.phiab.se
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.